HD
HDFC Pharma And Healthcare Fund Direct Growth
Latest NAV
+26.61% 1Y
Sign In to Add to Portfolio
Benchmark: BSE Healthcare TRI
Expense ratio
1.08%
AUM
₹3,311 Cr
Min SIP
₹100
Min lump sum
₹100
1Y
+26.61%
3Y (ann.)
+0.00%
5Y (ann.)
+0.00%
Launched
Oct 2023
Where the NAV sits & how risky it is
₹21.98
52-week range
at 85%
₹21.98
Low 02 Dec 2024₹16.83
High 21 Sep 2026₹22.89
Risk level
Very High
Low
Very high
NAV history
05 Oct 2023
Since inception
01 Oct 2026
Returns by period
1W
-3.18%
1M
-1.96%
3M
+4.49%
6M
+25.98%
1Y
+26.61%
3Y
+0.00%
5Y
+0.00%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹100
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 98.70%
Cash & other 1.67%
Sector split
Country split
Top 5 hold 33.1%
Top 10 hold 54.6%
33 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
9.20%
|
+4.52% |
| 2 | Divis Laboratories
INE361B01024 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
8.02%
|
+3.85% |
| 3 | Lupin
INE326A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.45%
|
+6.53% |
| 4 | Max Healthcare Institute
INE027H01010 |
Healthcare Medical Care Facilities |
India |
5.26%
|
-3.35% |
| 5 | Aster DM Healthcare
INE914M01019 |
Healthcare Medical Care Facilities |
India |
5.18%
|
+32.27% |
| 6 | Cipla
INE059A01026 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.92%
|
-8.03% |
| 7 | Acutaas Chemicals
INE00FF01025 |
Basic Materials Specialty Chemicals |
India |
4.50%
|
+88.80% |
| 8 | Alkem Laboratories
INE540L01014 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.36%
|
-2.98% |
| 9 | Anthem Biosciences
INE0CZ201020 |
Healthcare Biotechnology |
India |
4.15%
|
+17.58% |
| 10 | IPCA Laboratories
INE571A01038 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.50%
|
+14.89% |
About this scheme
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. There is no assurance that the investment objective of the Scheme will be realized.
Fund manager(s): Dhruv Muchhal, Nikhil Mathur
Exit load: Exit load of 1%, if redeemed within 30 days.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
04 Oct 2023
Lump-sum min
₹100
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 94.9 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 6.8 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 4.0 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 4.0 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 2.6 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 2.5 pts ahead of this fund